Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Terminated 2Completed 2Withdrawn 1Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Lymphoid 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1Dermatologic 1Classical hematology 1

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Carboplatin 158Pemetrexed 135Cisplatin 115pembrolizumab 99Docetaxel 94Paclitaxel 89Gemcitabine 63Erlotinib Hydrochloride 60Radiotherapy 55Nivolumab 55Bevacizumab 46Etoposide 42atezolizumab 33Radiosurgery 33durvalumab 28Cyclophosphamide 22Vinorelbine 21Ipilimumab 21Radiation 20Taxes 17130-nm albumin-bound paclitaxel 17Albumin-Bound Paclitaxel 16Gefitinib 14Irinotecan 13Drug Therapy 13osimertinib 12avelumab 12Magnetic Resonance Spectroscopy 12Dexamethasone 12Cetuximab 12

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × itacitinib × Thoracic × Clear all
NCT02257619 2026-04-21

Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung Cancer

Incyte Corporation

Phase 2 Terminated
9 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03425006 2023-09-13

Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer

University of Pennsylvania

Phase 2 Terminated
23 enrolled 12 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡